Functional variants of the pentraxin 3 gene are associated with the metastasis and progression of prostate cancer.
Wei-Chun WengYi-Hsien HsiehChia-Yen LinYu-Fan LiuShih-Chi SuShian-Shiang WangChiao-Wen LinPublished in: Journal of cellular and molecular medicine (2024)
Age, ethnic background and genetic components have been identified as the established risks for prostate cancer (PCa). Pentraxin 3 (PTX3), originally identified as a pattern-recognition molecule for defence against infectious agents, has multiple functions in tissue repair and in the regulation of cancer-associated inflammation. In this study, we sought to investigate the impact of PTX3 gene variants on the development of PCa. Genotypes of four common single-nucleotide polymorphisms (SNPs) of PTX3 gene, including rs1840680, rs2305619, rs3816527 and rs2120243, were profiled among 705 PCa patients and 705 ethnicity-matched controls. In this study, we found that patients who carry at least one minor allele (C) of rs3816527 (AC and CC) tended to develop advanced forms of diseases (clinical large T stage, OR, 1.593, p = 0.032; pathologically-confirmed nodal spread, OR, 1.987, p = 0.011; metastatic tumour, OR, 3.896, p = 0.032) as compared with those homologous for the major allele (AA). Further stratification analysis showed that such association of rs3816527 with lymphatic and distal metastasis of PCa was accentuated in the younger age group (≤65 at diagnosis) but not seen in the older age group (>65 at diagnosis), suggesting an age-specific effect of PTX3 variants. Prediction of PTX3 protein structure implied that polymorphism may alter the quaternary organization and oligomerization of PTX3 protein. Moreover, our gene silencing experiments and survey of public datasets revealed that elevation of PTX3 levels in PCa was required for cell migration and associated with tumour metastasis. Our results highlight an association of PTX3 rs3816527 with the progression of PCa.
Keyphrases
- copy number
- prostate cancer
- genome wide
- cell migration
- small cell lung cancer
- lymph node
- ejection fraction
- dna damage
- neoadjuvant chemotherapy
- prognostic factors
- risk assessment
- transcription factor
- rna seq
- climate change
- cross sectional
- community dwelling
- rectal cancer
- patient reported outcomes
- adverse drug
- genome wide analysis
- locally advanced